Emerging Microbes & Infections is a premier open access journal, published by Taylor & Francis Ltd since 2012, dedicated to advancing the understanding of microbial infections and their implications in human health. With an impressive Q1 ranking across multiple categories—including Drug Discovery, Epidemiology, Immunology, and Infectious Diseases—this journal is at the forefront of research in the microbiological sciences. Covering a diverse range of topics, it serves as a vital resource for researchers, healthcare professionals, and students alike. The journal's commitment to open access ensures worldwide dissemination of cutting-edge findings, fostering collaboration and innovation in tackling challenges posed by emerging infections. As part of the thriving academic community in the United Kingdom, Emerging Microbes & Infections plays a crucial role in shaping the future of infectious disease research and public health.

Welcome to the Jundishapur Journal of Microbiology, a peer-reviewed publication dedicated to advancing the field of microbiology. Published by BRIEFLAND, this journal focuses on key areas such as infectious diseases and medical microbiology, offering a platform for researchers to share their findings from 2009 to 2024. Despite its current positioning in Quartile 4 across various categories in 2023, the journal provides a valuable resource for budding scientists and established professionals alike, contributing to the growing body of knowledge in these critical areas. While it is not an open-access journal, the Jundishapur Journal prioritizes the dissemination of research in the Netherlands, facilitating a deeper understanding of microbial science and its implications for public health. Join a community of innovators committed to exploring both emerging and established themes in microbiology.

mSphere is a leading open-access journal published by the American Society for Microbiology, dedicated to the dynamic fields of Microbiology and Molecular Biology. Since its inception in 2016, mSphere has rapidly established itself as a reputable source of scholarly research, achieving notable impact factors and excellence within the academic community. The journal ranks in the top quartile (Q1) amongst its peers in Microbiology, and Q2 in the field of Molecular Biology, demonstrating its significance and relevance through Scopus rankings—specifically, it holds the #42 spot out of 182 in the Microbiology category and #108 out of 410 in Molecular Biology. With an editorial commitment to advancing the understanding of microbial and molecular sciences, mSphere provides an accessible platform for researchers, professionals, and students alike to disseminate groundbreaking findings. The journal promotes rigorous peer-review and invites innovative contributions aimed at enhancing microbial research mobility and molecular exploration. Accessible openly since 2016, mSphere continues to thrive as an influential publication driving scientific dialogue and discovery in the microbiological sciences.

Microbial Drug Resistance, published by MARY ANN LIEBERT, INC, is a pivotal journal that explores the critical intersection of microbiology and pharmacology with a keen focus on antibiotic resistance and related issues. Since its inception in 1995, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for innovative studies that inform the global response to antimicrobial resistance. With a commendable position in the Category Quartiles, ranked Q2 in Medicine (miscellaneous) and Q2 in Pharmacology for 2023, it caters to a multidisciplinary audience by addressing the implications of microbial resistance within various medical contexts. Although currently non-Open Access, the journal allows subscribers and institutions to access high-quality, peer-reviewed research, directly impacting policy and practice in healthcare settings. Committed to advancing our understanding and combating the challenges posed by resistant microbes, Microbial Drug Resistance remains an essential publication in the fields of microbiology, immunology, and pharmacology.

Comparative Immunology Microbiology and Infectious Diseases, published by Elsevier Science Ltd, is a prominent journal dedicated to advancing the fields of immunology, microbiology, infectious diseases, and veterinary sciences. Established in 1978, this journal has become a vital resource for researchers and professionals alike, with a commendable impact factor that reflects its significance in academia. The journal, available in both print and electronic formats (ISSN: 0147-9571, E-ISSN: 1878-1667), stands out for its commitment to disseminating innovative research findings, particularly through its categorization in Q2 and Q3 quartiles across various related disciplines as of 2023. The journal aims to provide insightful comparative analyses that enhance our understanding of host-pathogen interactions, immune responses, and disease manifestations. With a global readership base, it serves as a platform for collaborative discourse among scientists and professionals, ultimately contributing to the improvement of health outcomes worldwide.

GERMS is a multidisciplinary journal published by the EUROPEAN ACAD HIV-AIDS & INFECTIOUS DISEASES, dedicated to advancing knowledge in the fields of epidemiology, immunology, infectious diseases, and microbiology. Since its inception in 2011, the journal has provided a crucial platform for researchers and practitioners to share innovative studies, clinical findings, and public health insights, with an eye on improving health outcomes globally. With an ISSN of 2248-2997 and a consistent publication trajectory leading up to 2024, GERMS is recognized in the third quartile across several categories, reflecting its growing impact and relevance in the scientific community. Authors and readers benefit from a range of access options, fostering the dissemination of vital research findings. As a journal situated in Romania, it also addresses regional health challenges while contributing to the broader discourse on infectious diseases and public health. GERMS is not just a repository of knowledge, but a vital resource for those engaged in combating infectious diseases and promoting health equity.

New Microbes and New Infections is an esteemed peer-reviewed journal published by Elsevier Sci Ltd that has been a prominent platform for disseminating groundbreaking research in the fields of Infectious Diseases and Microbiology since its establishment in 2013. With an impressive Open Access model, this journal ensures that vital research findings are readily accessible to researchers, healthcare professionals, and academics worldwide. Positioned in the Q2 category for Infectious Diseases and Q3 for Microbiology in 2023, it reaches a significant global audience, as demonstrated by its high Scopus rankings—#44 out of 344 in Medicine: Infectious Diseases, and #34 out of 182 in Immunology and Microbiology. The journal aims to inspire new ideas and foster collaborations by publishing high-quality research focused on novel microbes and infections, thus playing a crucial role in advancing science and public health in an era where understanding infectious agents is more vital than ever.

The BRAZILIAN JOURNAL OF MICROBIOLOGY, published by SPRINGER, stands as a pivotal platform in the field of microbiology, offering an open access model since 2000. With the ISSN 1517-8382 and E-ISSN 1678-4405, this esteemed journal encourages the dissemination of groundbreaking research and innovative methodologies that contribute to the understanding of microbial life, its role in health and disease, and its environmental impact. Based in Switzerland and accessible globally, the journal’s categorization in the Q3 quartile for Microbiology reflects its commitment to quality and relevance in the scientific community. As of 2023, it ranks 121 out of 182 in the Scopus listings for Microbiology, further highlighting its growing influence in immunology and microbiological research. With converged years spanning from 1992 to 2024, the journal continues to support a diverse range of studies, making it an invaluable resource for researchers, professionals, and students alike.

Current Clinical Microbiology Reports, published by Springer, is a leading international journal dedicated to advancing the field of clinical microbiology. With a focus on the diagnosis, treatment, and prevention of infectious diseases, this journal serves as a vital resource for researchers, medical professionals, and students engaged in microbiological studies. As a testament to its quality and influence, it holds an impressive impact factor and ranks in the Q1 category in both Infectious Diseases and Microbiology (medical), reflecting its prominent standing in the scholarly community. Additionally, it features a commendable Scopus ranking, placing it in the 77th percentile for Medicine - Infectious Diseases and the 69th percentile for Medicine - Microbiology (medical). With contributions spanning over a decade, from 2014 to 2024, the journal continues to publish high-quality research articles that shape the future of clinical practices and public health policies. While access options are variable, the journal's commitment to open dialogue and dissemination of knowledge makes it a pivotal platform for those passionate about tackling microbial challenges in healthcare.

Welcome to the International Journal of Medical Microbiology, a leading publication in the field of microbiological research and infectious diseases, offered by Elsevier GmbH. Established in 2000, this esteemed journal provides a scholarly platform for the presentation of high-quality research, reviews, and innovations that bridge medical microbiology and clinical applications. With an impressive impact factor positioning it within the Q1 category across multiple disciplines, including Infectious Diseases, Microbiology, and Medicine, the journal is recognized for its rigorous peer-review process and significant contributions to advancing our understanding of microbial pathogenesis, diagnostics, and therapeutics. The International Journal of Medical Microbiology is committed to open access, promoting the dissemination of knowledge and accessibility for researchers, professionals, and students worldwide. Based in Munich, Germany, the journal continues to play a vital role in the global scientific community, fostering collaborations and inspiring future innovations in the fight against infectious diseases.